{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"48.9","value":"22.43"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"8.1","value":"6.20"},{"groupId":"OG002","lowerLimit":"3.9","upperLimit":"169.1","value":"29.82"},{"groupId":"OG003","lowerLimit":"7.7","upperLimit":"183.1","value":"83.22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"77"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"Time to progression (TTP) was defined as the time from the date of first dose to the date of first documentation of progressive disease (PD).\n\nPD:\n\n* Increase of 25% or more from nadir in serum M-protein, absolute increase of \\>= 0.5 g/dL.\n* Increase of 25% or more from nadir in 24-hour urinary M-protein, absolute increase of \\>=200 mg/24 hours.\n* Increase of 25% or more in the percentage of bone marrow plasma cells, absolute increase of \\>=10%.\n* New bone lesions or soft tissue plasmacytomas or increase size of existing bone lesions or soft tissue plasmacytomas.\n* Hypercalcemia attributed to myeloma.","dispersionType":"Full Range","groups":[{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Phase 1b - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG001","title":"Phase 1b - ACY-1215 Dose Level 3"},{"description":"Participants received 160 mg ACY-1215 and 4 mg pomalidomide daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG002","title":"Phase 2 - ACY-1215 Dose Level 1"},{"description":"Participants received 160 mg ACY-1215 twice daily in combination with 4 mg pomalidomide once daily on Days 1-21 of each 28-day cycle. Participants also received 40 mg (\\<=75 years) or 20 mg (\\>75 years) dexamethasone on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG003","title":"Phase 2 - ACY-1215 Dose Level 3"}],"paramType":"MEAN","populationDescription":"All treated participants in the Efficacy Evaluable population who had PD.","reportingStatus":"POSTED","timeFrame":"From first dose until disease progression, study drug toxicity, end of study, or death due to any cause (up to approximately 120 months).","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"Weeks"}